Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-H0731 long-term extension with nucleos(t)ide finite therapy in chronic hepatitis B
2018-004019-34Phase 2Unknown
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebicorvir in Chronic Hepatitis B (CHB), sponsored by Assembly Biosciences, Inc. Primary endpoint: Sustained virologic response at 24 weeks off treatment. Status: unknown.
02
Drugs
vebicorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2018-004019-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004019-34.